- Research article
- Open Access
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers
Journal for ImmunoTherapy of Cancer volume 7, Article number: 146 (2019)
Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug chemotherapy regimen represents the treatment cornerstone; however, cure is rarely achieved. We have been treating dogs with B-cell lymphoma with an autologous vaccine (APAVAC®) and CHOP-based chemotherapy since 2011.
To better characterize the safety and efficacy of APAVAC®, and to find the best candidates for immunotherapy, we designed a retrospective study on all dogs treated with chemo-immunotherapy to date and compared them with those dogs treated with chemotherapy only. All dogs were completely staged and re-staged at the end of treatment. The primary endpoint was the effectiveness of chemo-immunotherapy, measured as time to progression (TTP), lymphoma-specific survival (LSS), and 1-, 2-, and 3-year survival rates. The secondary objective was safety.
Three hundred dogs were included: 148 (49.3%) received chemotherapy and 152 (50.7%) chemo-immunotherapy. Overall, the latter survived significantly longer (median LSS, 401 vs 220; P < 0.001).
Among dogs with diffuse large B-cell lymphoma, the 1-, 2- and 3-year survival rates were 20, 13 and 8% for chemotherapy, and 51, 19 and 10% for chemo-immunotherapy. The benefit of chemo-immunotherapy was particularly relevant in dogs with concurrent high serum LDH, stage V, substage a disease and not previously treated with steroids (median LSS, 480 vs 85 days; P < 0.001). Among dogs with nodal marginal zone lymphoma, those having at least 3 of the aforementioned characteristics significantly benefited from chemo-immunotherapy (median LSS, 680 vs 160 days, P < 0.001). The 1-, 2- and 3-year survival rates were 30, 16 and 10% for chemotherapy, and 55, 28 and 10% for chemo-immunotherapy. Among dogs with follicular lymphoma, lack of immunotherapy administration was the only variable significantly associated with increased risk of tumor-related death. Chemo-immunotherapy was remarkably well tolerated, with no local or systemic adverse events.
Overall, the addition of immunotherapy to a traditional CHOP protocol is associated with improved outcome in dogs with B-cell lymphoma, regardless of histotype and evaluated prognostic factors. Moreover, the identikit of the best candidate for immune-therapy was delineated for the most common histotypes. The study also confirms the excellent tolerability of the vaccine.
Pet dogs most often spontaneously develop B-cell lymphoma , for which survival without treatment is measured in weeks or months. Anthracycline-based multidrug chemotherapy represents the cornerstone for the treatment of canine B-cell lymphoma across all disease stages; however, the majority of dogs eventually relapses and develops chemo-resistance, and cure is rarely achieved .
Immunotherapy represents a powerful way to treat cancer, and the last decade has witnessed unprecedented advancements in the understanding of both the molecular drivers of lymphomagenesis and mechanisms by which lymphoma circumvents anti-tumor immunity [3, 4].
Active immunotherapy consisting of hydroxylapatite ceramic powder and HSPs purified from the dogs’ tumors (APAVAC®) has shown promising results in a pivotal placebo-controlled, randomized clinical trial in dogs with DLBCL . Within the first few years of its introduction to the European market, the investigational use of APAVAC® was extended to indolent B-cell lymphomas with suggestive signals of potential usefulness .
The aim of this retrospective study was to compare the efficacy and safety of chemotherapy alone versus chemo-immunotherapy in dogs with multicentric B-cell lymphoma of various histotypes in 5 years of clinical experience. The survival advantage of chemo-immunotherapy was further assessed after stratifying dogs according to potential prognostic variables, in order to identify the best candidates for vaccine administration.
Pooling the available clinical data should provide an accurate evaluation of the efficacy of chemo-immunotherapy in canine B-cell lymphoma compared with traditional chemotherapy, posing the basis for future clinical trial design and informing human trials.
Material and methods
Medical records were reviewed for every consecutive canine patient with previously untreated multicentric B-cell lymphoma that presented to the Centro Oncologico Veterinario (Sasso Marconi, Italy) and Department of Veterinary Medicine (University of Milan, Italy) from 2013 to 2018. This study was prospectively conceived and clinical data on the efficacy and toxicity of treatments were analyzed retrospectively, thus the inclusion criteria were established a priori and all dogs were treated contemporaneously.
To be eligible for inclusion, dogs were required to undergo a complete initial staging work-up and, whenever possible, surgical removal of a peripheral LN to obtain a histopathological diagnosis and material for the vaccine generation (Additional file 1). Based on histopathology and immunohistochemistry (CD20, CD3), tumors were classified according to the modified WHO criteria .
Also, dogs were only included, if information regarding treatment and outcome were complete.
As this evaluation did not influence any therapeutic decision, approval by an Ethics Committee was not required. Owners gave their written informed consent to the use of clinical data.
Briefly, dogs received l-asparaginase, vincristine, cyclophosphamide, doxorubicin, lomustine, prednisone, and a total of 8 intradermal injections of 0.5 ml vaccine.
For immunological monitoring, the DTH skin test was performed in all vaccinated dogs at the end of treatment (Additional file 1).
Unvaccinated dogs received two CHOP-based protocol, including l-asparaginase, vincristine, cyclophosphamide, doxorubicin, prednisone, with or without lomustine(Additional file 1); the intended summation dose intensity of these two protocols was 16.8 and 16.9, respectively. Thus, they were considered identical and evaluated as a whole.
Response assessment and minimal residual disease monitoring
Response was evaluated at each treatment session according to previously published criteria .
Two weeks after having completed the protocol, all dogs underwent restaging by repeating the initially altered examination. For minimal residual disease monitoring, FC on PB, BM and a LN aspirate was carried out [11, 12]. Dogs were then rechecked through monthly physical examinations during the first year, and every other month thereafter.
Relapse was defined as clinical reappearance and cytological evidence of lymphoma in any anatomical site in dogs having experienced CR, whereas relapse for animals with PR was defined as progression.
Dogs that relapsed during or after treatment were offered rescue chemotherapy.
The primary study objectives were the effectiveness of chemo-immunotherapy in dogs with B-cell lymphoma, measured as TTP, LSS, and 1-, 2-, and 3-year survival rates. This was evaluated in the whole population and by stratifying dogs according to potential prognostic variables, in order to select the best candidates for chemo-immunotherapy.
The secondary objective was safety (measured by recording any AE and/or hospitalization that occurred during or immediately after treatment). All AEs were registered at the time of occurrence, and graded according to VCOG .
Descriptive statistics were used in the analysis of dogs and tumor characteristics. The distribution of demographic features and possible outcome variables between treatment groups were assessed with Fisher’s exact test/χ2 test (categorical variables).
Variables considered were: sex, age, weight, PCV, platelet count, serum LDH activity, serum Ionized calcium concentration, substage, PB infiltration, BM infiltration, extranodal site involvement, and pre-treatment with steroids.
TTP was calculated as the interval between initiation of treatment and PD or relapse; dogs with no PD or relapse at data-analysis closure or death were censored. LSS was measured as the interval between initiation of treatment and death or euthanasia for lymphoma or chemo-related causes. Dogs deceased for lymphoma-unrelated causes or alive at data-analysis closure were censored. Survival plots were generated according to the Kaplan-Meier product-limit method. Curves were compared with the log-rank test. The influence of potential prognostic variables on tumor progression and tumor-related death was investigated with univariable and multivariable Cox’s regression analysis.
The survival advantage of vaccine administration was further tested upon stratification of cases according to the other considered variables. The variables with no survival advantage for one of the strata were selected for a scoring system to quantify the utility of vaccine administration. Dogs with the highest score were the best candidates for immunotherapy.
Data were analyzed by use of commercial software programs (SPSS Statistics v19, IBM, Armonk, NY, USA, Prism v.5.0, GraphPad, San Diego, California). P-values < 0.05 were considered significant.
The total population consisted of 300 dogs: 246 (82%) underwent lymphadenectomy, whereas in the remaining 54 (18%) a cytological and FC diagnosis only was obtained.
Within the histology group, DLBCL was the most common histotype (n = 148; 60.2%), followed by nodal MZL late stage (n = 49; 19.9%), FL (n = 25; 10.2%), Burkitt lymphoma (n = 10; 4.1%), SLL (n = 8; 3.3%), and lymphoblastic lymphoma (n = 6; 2.4%).
Within the cytology group, there were 50 (92.6%%) centroblastic/immunoblastic lymphomas, 2 (3.7%) lymphoblastic lymphomas, and 2 (3.7%) medium macronucleolated cell lymphomas.
Within the whole population, 148 (49.3%) dogs received chemotherapy alone and 152 (50.7%) chemo-immunotherapy.
Median TTP was 147 days (95% CI, 111–183) for dogs receiving chemotherapy and 244 days (95% CI, 218–270) for those receiving chemo-immunotherapy (P < 0.001). Median LSS was 220 days (95% CI, 157–243) for dogs receiving chemotherapy and 401 days (95% CI, 339–463) for those receiving chemo-immunotherapy (P < 0.001).
The three main histotypes are detailed in the following paragraphs.
Dogs with diffuse large B-cell lymphoma
Table 1 provides a summary of the characteristics of 148 dogs with DLBCL using known or potential covariates for outcome.
Forty (27%) dogs had been treated with steroids before referral. Forty-seven (31.8%) were treated with chemotherapy and 101 (68.2%) received chemo-immunotherapy. There was a good balance between treatment arms regarding demographic information and possible outcome variables, including the number of rescue protocols, with the exception of a lower percentage of dogs with extranodal involvement in the chemo-immunotherapy group (Table 1).
Median TTP was 98 days (95% CI, 9–187) for dogs receiving chemotherapy and 250 days (95% CI, 210–290) for those receiving chemo-immunotherapy (P = 0.001). Median LSS was 165 days (95% CI, 107–223) for dogs receiving chemotherapy and 413 days (95% CI, 316–510) for those receiving chemo-immunotherapy (P = 0.001).
There was no significant difference in TTP and LSS between dogs with positive and negative DTH test.
The 1-year, 2-year and 3-year survival rates were, respectively, 20, 13 and 8% for the chemotherapy group, and 51, 19 and 10% for the chemo-immunotherapy group.
On multivariable analysis, lack of immunotherapy administration was significantly associated with an increased risk of tumor progression (HR = 2.3, 95% CI = 1.4–3.6, P = 0.001) and tumor-related death (HR = 2.6, 95% CI = 1.6–4.2, P < 0.001). The benefit of chemo-immunotherapy was particularly relevant in dogs with high serum LDH levels, stage V disease, substage a, and not previously treated with steroids.
The patients with all of the above characteristics obtained the greatest survival advantage from the administration of immunotherapy (median LSS, 480 vs 85 days; P < 0.001). Among dogs falling in two or three of the above categories, those treated with chemo-immunotherapy still had a significantly better outcome, but the survival advantage was reduced (median LSS, 435 vs 190 days; log-rank, P = 0.030). Finally, dogs falling in one or none of the above categories did not receive any significant benefit from immunotherapy (median LSS, 374 vs 286 days, log-rank, P = 0.573; Table 2; Fig. 1).
Dogs with nodal marginal zone lymphoma
Table 1 provides a summary of the characteristics of 49 dogs with MZL using known or potential covariates for outcome.
Twelve (24.5%) dogs had been treated with steroids before referral.
Twenty-four (48.9%) dogs received chemotherapy alone and 25 (51.1%) chemo-immunotherapy. Dogs were evenly balanced between groups according to possible outcome variables, including the number of rescue protocols, with the exception of a lower percentage of dogs receiving steroids before being treated with chemo-immunotherapy (Table 1).
Median TTP was 147 days (95% CI, 47–247) for dogs receiving chemotherapy and 227 days (95% CI, 165–289) for those receiving chemo-immunotherapy (P = 0.082). Median LSS was 254 days (95% CI, 69–442) for dogs receiving chemotherapy and 399 days (95% CI, 133–665) for those receiving chemo-immunotherapy (P = 0.245).
There was no significant difference in TTP and LSS between dogs with positive and negative DTH test.
The 1-year, 2-year and 3-year survival rates were, respectively, 30, 16 and 10% for the chemotherapy group and 55, 28 and 10% for the chemo-immunotherapy group.
When including in the survival analysis only the dogs falling in at least three of the 4 categories identified for DLBCL, the survival advantage of chemo-immunotherapy was statistically significant (median LSS, 680 vs 160 days, log-rank, P < 0.001; Table 2; Fig. 1).
Dogs with follicular lymphoma
Among the 25 dogs with FL, 4 (16%) had been treated with steroids before being referred.
Six (24%) dogs were treated with chemotherapy and 19 (76%) received chemo-immunotherapy. There was a good balance between treatment arms regarding demographic information and possible outcome variables, including the number of rescue protocols (Table 1).
Median TTP was 168 days (95% CI, 1–386) for dogs receiving chemotherapy and 273 days for those receiving chemo-immunotherapy (P = 0.076). Median LSS was 200 days (95% CI, 1–462) for dogs receiving chemotherapy and 436 days (95% CI, 201–671) for those receiving chemo-immunotherapy (P = 0.011).
The 1-year, 2-year and 3-year survival rates were 0% for the chemotherapy group, and 36, 27 and 18% for the chemo-immunotherapy group.
On multivariable survival analysis, lack of immunotherapy was the only variable significantly associated with increased risk of tumor-related death (HR = 5.2; 95% CI = 1.1–25.2; P = 0.039).
All dogs included in the study were evaluable for toxicity.
Immunotherapy was well tolerated, with no reported local or systemic AEs.
Chemotherapy was similarly well tolerated. There was no significant difference among groups regarding grade and frequency of AEs (Table 1).
Immunotherapy is increasingly acknowledged as an effective treatment for several canine cancers including, malignant melanoma, B-cell lymphoma, osteosarcoma, and brain tumors [7, 8, 14,15,16,17,18,19,20,21,22]. Studies in the field have unfortunately shown that not all dogs will have a substantial benefit, and it is incumbent upon clinicians to decide whether a dog is or is not a candidate for immunotherapy.
Herein, we present the results of a study aimed at comparing the outcomes of dogs with B-cell lymphoma receiving chemotherapy or chemo-immunotherapy. The primary goal of this study was to identify the candidate dogs that would benefit the most from chemo-immunotherapy in the standard daily clinical practice outside a trial setting. So far only two small clinical trials on chemo-immunotherapy have been reported [7, 8]. The current study ranks among the largest per number of dogs treated with the same product for a specific disease and confirms the efficacy and the good safety profile of this treatment.
It was herein confirmed that DLBCL is the most common histotype in dogs, followed by MZL and FL. By analyzing the whole population it was also confirmed that stage III disease is quite infrequent, whereas stage V was most commonly diagnosed (70.7%). It is likely that an accurate staging leads to stage migration, having prognostic and therapeutic implications, as documented by the current data.
Overall, the present study demonstrates a significant clinical benefit of immunotherapy. In particular, subgroup analysis of LSS, comparing treatment arms using a multivariable method, indicated the following.
It was found that immunotherapy conferred a survival benefit in the majority of DLBCL cases. However, dogs that benefited the most were those with stage V disease, no systemic symptoms, a high serum LDH, and not previously treated with steroids. Interestingly, if these characteristics were concurrent, vaccinated dogs had the highest survival advantage (480 vs 85 days, respectively).
If two or three of the abovementioned characteristics were present, the survival benefit for vaccinated dogs was still significant, although to a lesser extent (435 vs 190 days, respectively). If only one or none of the abovementioned characteristics were present, there was no demonstrable benefit of chemo-immunotherapy over chemotherapy, although these cases represented a minority (n = 22).
It could be hypothesized that the stimulation of the immune system may contribute to counteract the negative impact of well-known prognostic factors that commonly lead to a poor outcome if chemotherapy only is administered. While chemotherapy effects only last as long as the drugs remain in the body, immunotherapy can provide long-term protection against cancer due to the immune memory, overcoming the “honeymoon effect” provided in the short term by cytotoxic drugs, more over if negative prognostic factors are present. Chemotherapy fails when drug-resistant clones emerge, preventing tumor cell eradication . It may be possible that dogs with negative prognostic factors, such as advanced disease stage and high LDH levels, are more susceptible of developing chemo-resistance [2, 24, 25]. In these dogs, chemo-resistant clones may be eliminated by cell-mediated immunotherapy because they can evade neither immune surveillance nor immune response, thereby providing a survival benefit.
Finally, the lower immunity in symptomatic dogs is a plausible explanation to the suboptimal response to immunotherapy, and specific immune responses may be abrogated by pre-treatment steroids.
These findings were also confirmed for the MZL cases: vaccinated dogs survived significantly longer than unvaccinated dogs (680 vs 160 days, respectively; P < 0.001) if three or four of the previously identified characteristics were present. If 2 to none of those were present, there was no significant benefit in administering chemo-immunotherapy over chemotherapy.
In dogs with FL, a survival benefit of vaccine-administration was demonstrated as well, however the population was too small to evaluate the potential inference of other prognostic factors.
Finally, it must be reminded that, although chemo-immunotherapy seems to provide better results than chemotherapy for the majority canine B-cell lymphomas, the 3-year survival rate remains largely unsatisfactory, ranging from 0 to 12%; whereas the largest survival benefit can be experienced in the short/medium-term period. It is currently unknown whether re-vaccination or preparation of a new vaccine starting from nodal relapses would improve long-term survival.
Our study has a number of limitations, such as the small number of dogs included in some of the categories and its retrospective nature. However, we have included consecutive dogs diagnosed following a uniform approach and treated with standardized protocols.
Third, the evaluation of the immune response by the DTH skin test, albeit clinically relevant, is operator-dependent. Standardized and quantitative analyses are warranted to reduce this constraint.
Last, LSS may have been influenced by tumor’s unrelated factors, including owners’ motivation and financial concern. However, almost all dogs in both treatment arms received at least one rescue protocol, thereby reducing the risk of bias.
Our study shows a response and survival benefit of the addition of active immunotherapy to chemotherapy in dogs with B-cell lymphoma, possibly due to a different and perhaps synergistic mechanism of action. In the future, the development of new effective immunotherapeutic strategies should take into account differences in immune microenvironment between different lymphoma molecular subtypes to find the best treatment for each patient. A large-scale, double-blinded, randomized, multi-institutional trial is essential for ascertaining the efficacy of the presently described active immunotherapy procedure and its clinical application.
Availability of data and materials
All data generated or analysed during this study are included in this published article [and its Additional file].
Diffuse large B-cell lymphoma
Heat Shock Proteins
Marginal zone lymphoma
Overall response rate
Packed cell volume
Small lymphocytic lymphoma
Time to progression
Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, Pastor M, Delignette ML, Fournel-Fleury C. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol. 2010;47(3):414–33.
Marconato L, Stefanello D, Valenti P, Bonfanti U, Comazzi S, Roccabianca P, Caniatti M, Romanelli G, Massari F, Zini E. Predictors of long-term survival in dogs with high-grade multicentric lymphoma. J Am Vet Med Assoc. 2011;238(4):480–5.
Aricò A, Ferraresso S, Bresolin S, Marconato L, Comazzi S, Te Kronnie G, Aresu L. Array-based comparative genomic hybridization analysis reveals chromosomal copy number aberrations associated with clinical outcome in canine diffuse large B-cell lymphoma. PLoS One. 2014;9(11):e111817.
Aresu L, Ferraresso S, Marconato L, Cascione L, Napoli S, Gaudio E, Kwee I, Tarantelli C, Testa A, Maniaci C, et al. New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease. Haematologica. 2018 Dec 13. https://doi.org/10.3324/haematol.2018.207027.
Marron TU, Ronner L, Martin PE, Flowers CR, Brody JD. Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. Immunotherapy. 2016;8(11):1335–46.
Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW. Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines. 2006;5(3):381–94.
Marconato L, Frayssinet P, Rouquet N, Comazzi S, Leone VF, Laganga P, Rossi F, Vignoli M, Pezzoli L, Aresu L. Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma. Clin Cancer Res. 2014;20(3):668–77.
Marconato L, Stefanello D, Sabattini S, Comazzi S, Riondato F, Laganga P, Frayssinet P, Pizzoni S, Rouquet N, Aresu L. Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma. Vaccine. 2015;33(39):5080–6.
Valli VE, San Myint M, Barthel A, Bienzle D, Caswell J, Colbatzky F, DurhamA, Ehrhart EJ, Johnson Y, Jones C, et al. classification of canine malignant lymphomas according to the World Health Organization criteria. Vet Pathol 2011; 48: 198–211.
Vail DM, Michels GM, Khanna C, Selting KA. London CA; veterinary cooperative oncology group. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2010;8(1):28–37.
Aresu L, Aricò A, Ferraresso S, Martini V, Comazzi S, Riondato F, Giantin M, Dacasto M, Guadagnin E, Frayssinet P, et al. Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma. Vet J. 2014;200(2):318–24.
Chalfon C, Martini V, Comazzi S, Aresu L, Stefanello D, Riondato F, Ferrari R, Marconato L. Minimal residual disease in lymph nodes after achievement of complete remission predicts time to relapse in dogs with large B-cell lymphoma. Vet Comp Oncol. 2018 Dec 21. https://doi.org/10.1111/vco.12453.
Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14(4):417–46.
Andersen BM, Pluhar GE, Seiler CE, Goulart MR, SantaCruz KS, Schutten MM, Meints JP, O'Sullivan MG, Bentley RT, Packer RA, et al. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Res. 2013;73(10):2987–97.
Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res. 2003;9(4):1284–90.
Turek MM, Thamm DH, Mitzey A, Kurzman ID, Huelsmeyer MK, Dubielzig RR, Vail DM. Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma. Vet Comp Oncol. 2007;5(4):219–31.
Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto G, La Monica N, Aurisicchio L. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol Ther. 2010;18(8):1559–67.
Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res. 2011;72(12):1631–8.
Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS One. 2011;6(8):e24167.
Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M, De Maria R, Gattino F, Lanzardo S, et al. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res. 2014;20(14):3753–62.
Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y. Immunotherapy with a HER2-targeting Listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res. 2016;22(17):4380–90.
Wycislo KL, Fan TM. The immunotherapy of canine osteosarcoma: a historical and systematic review. J Vet Intern Med. 2015;29(3):759–69.
Zandvliet M, Teske E. Mechanisms of drug resistance in veterinary oncology- a review with an emphasis on canine lymphoma. Vet Sci. 2015;2(3):150–84.
Lana SE, Jackson TL, Burnett RC, Morley PS, Avery AC. Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. J Vet Intern Med. 2006;20(2):329–34.
Marconato L, Martini V, Aresu L, Sampaolo M, Valentini F, Rinaldi V, Comazzi S. Assessment of bone marrow infiltration diagnosed by flow cytometry in canine large B cell lymphoma: prognostic significance and proposal of a cut-off value. Vet J. 2013;197(3):776–81.
The authors declare that they have no funding.
Ethics approval and consent to participate
As this retrospective evaluation did not influence any therapeutic decision, approval by an Ethics Committee was not required. All the examined samples were collected for diagnostic purposes as part of routine standard care. Owners gave their written informed consent to the use of clinical data.
Consent for publication
NR and PF are employees of the company that had developed and commercializes APAVAC. There are no further competing interests to declare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Marconato, L., Aresu, L., Stefanello, D. et al. Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers. j. immunotherapy cancer 7, 146 (2019) doi:10.1186/s40425-019-0624-y
- Spontaneous cancer
- Follicular lymphoma
- Cancer immunotherapy
- Autologous vaccine